New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
07:22 EDTBINDBIND Therapeutics barasertib data positive, says JMP Securities
JMP Securities notes that pre-clinical studies of BIND's barasertib showed enhanced anti-tumor activity and reduced bone marrow toxicity. The firm thinks the company could overcome the need for lengthy drug infusion and high rates of febrile neutropenia, shown in a previous studiy, by extending the half-life of the drug. The firm reiterates a $30 price target and Outperform rating on the stock.
News For BIND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
11:23 EDTBINDBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use